The current excitement about molecular targeted therapies has driven much of the recent dialog in cancer diagnosis and treatment. Particularly in the biologic therapy of cancer, identifiable antigenic T-cell targets restricted by MHC molecules and the related novel stress molecules such as MICA/B and Letal allow a degree of precision previously unknown in cancer therapy. We have previously held workshops on immunologic monitoring and angiogenesis monitoring. This workshop was designed to discuss the state of the art in identification of biomarkers and surrogates of tumor in patients with cancer, with particular emphasis on assays within the blood and tumor.Authors: Michael T. Lotze, Ena Wang, Francesco M. Marincola, Nabil Hanna, Peter J. Bugelski, Christine A. Burns, George Coukos, Nitin Damle, Tony E. Godfrey, Martin W. Howell, Monica C. Panelli, Michael A. Perricone, Emanuel F. Petricoin, Guido Sauter, Carmen Scheibenbogen, Steven C. Shivers, Lansing D. Taylor, John N. Weinstein, Theresa L. WhitesidePublished in the Journal of Immunotherapy (2005) 28:2.#SITCPublication